Melanoma Research Victoria

Source: OnClive, February 2019 Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma. An ongoing study is looking at combining PD-1 inhibition, specifically pembrolizumab (Keytruda), with antigen-presenting cells in an attempt to block 2 checkpoints concurrently. […]

Read the full story

Source: OncLive, February 2019 Transcript: Axel Hauschild, MD: We are already touching on the field of emerging strategies. There was some news this year from other conferences, as well as an abstract on anti–LAG-3 [lymphocyte-activation gene 3] as a second-line treatment option in patients who were progressive on PD-1 [programmed cell death protein 1] antibodies. Here, […]

Read the full story

Source: OncLive, February 2019 Transcript: Axel Hauschild, MD: At the end of our discussion, I want to touch on 2 new components with different modes of action. There is the NKTR component, which is called NKTR-214. There was a trial released at ASCO [American Society of Clinical Oncology Annual Meeting] on this. Merrick, are you familiar […]

Read the full story

Source: OncLive, February 2019 Transcript: Axel Hauschild, MD: In 2019, we are expecting to see the results of 2 large, randomized clinical trials on triplet regimens, namely the BRAF and MEK inhibitors, plus a PD-1 [programmed cell death protein 1] antibody and a PD-L1 [programmed death-ligand 1] antibody, respectively. Specifically, we are looking forward to results […]

Read the full story